Evidence map›Paper›PMID 36193072›Full record

ArticleOxidative medicine and cellular longevity2022

Pyrocatechol Alleviates Cisplatin-Induced Acute Kidney Injury by Inhibiting ROS Production.

Xuexia Xie, Fan Wu, Jiaxin Tian, Zhilong Liu, Huibin He, Dongping Bao, Guoliang Li, Haomin Li, Jianfan Chen, Yiqi Lai and 4 more

Abstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xuexia Xie *Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Fan Wu *Department of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Jiaxin TianDepartment of Medical Biochemistry and Molecular Biology, Engineering Technology Research Center of Drug Development for Small Nucleic Acids, School of Medicine, Jinan University, Guangzhou 510632, China.
Zhilong LiuDepartment of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou 510632, China.
Huibin HeDepartment of Urology, Dongguan Kanghua Hospital, Dongguan, China.
Dongping BaoDepartment of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Guoliang LiDepartment of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Haomin LiDepartment of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Jianfan ChenDepartment of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Yiqi LaiUniversity of South China, Hengyang, China.
Zheng ChenDepartment of Urology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.ORCID https://orcid.org/0000-0002-0931-0537
Jun FanDepartment of Medical Biochemistry and Molecular Biology, Engineering Technology Research Center of Drug Development for Small Nucleic Acids, School of Medicine, Jinan University, Guangzhou 510632, China.ORCID https://orcid.org/0000-0001-6637-9891
Guo ChenDepartment of Medical Biochemistry and Molecular Biology, Engineering Technology Research Center of Drug Development for Small Nucleic Acids, School of Medicine, Jinan University, Guangzhou 510632, China.ORCID https://orcid.org/0000-0001-8886-1873
Caiyong LaiDepartment of Urology, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.ORCID https://orcid.org/0000-0003-4679-0944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the most common cancer chemotherapy drugs, cisplatin is widely used in cancer management. However, cisplatin-induced nephrotoxicity occurs in patients who receive this drug. This study is aimed at developing therapeutic agents that effectively alleviate the nephrotoxic effects during cisplatin treatment. We identified a compound named pyrocatechol (PCL) from a natural product library that significantly alleviated cisplatin-induced cytotoxicity

Indexed as

Acute Kidney InjuryAntineoplastic AgentsBiological ProductsApoptosisCatecholsCisplatinHumansKidneyOxidative Stressp38 Mitogen-Activated Protein KinasesPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciesAntineoplastic AgentsBiological ProductsCatecholsCisplatinp38 Mitogen-Activated Protein KinasesPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen Species

Identifiers

PMID36193072
PMCPMC9526614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.